ReviewAlpha psychiatry2025
Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.
Review in Alpha psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia (SCZ) is a debilitating, chronic mental disorder with an elusive etiology that significantly impacts the life expectancy of affected individuals. Metabolic syndrome (MetS) is a condition characterized by a combination of factors that increase the risk of cardiovascular diseases. MetS is more prevalent in individuals with SCZ and is a major factor that contributes to their reduced lifespan. This review scrutinizes the biological factors that predispose patients with SCZ to MetS, among which, genetic predisposition, dietary and lifestyle modifications, and the use of antipsychotic drugs (APs) play a significant role. The metabolic side effects of APs have been well studied. While studies have shed light on potential interventions to manage MetS in patients with SCZ, identifying precise biological targets to treat SCZ remains challenging. Therefore, further studies are warranted to enhance our comprehension of the intricate mechanisms underlying the susceptibility of patients with SCZ to MetS. These studies will be crucial in developing effective, targeted therapeutic strategies to treat MetS in this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.